Sign In
Buy PROG
$0.94
-0.0340 (-3.48%)
At Close: Aug 17, 2022
Progenity, Inc. Prices $75.0 Million Convertible Senior Notes Offering
11:51pm, Wednesday, 02'nd Dec 2020
SAN DIEGO, Dec. 02, 2020 (GLOBE NEWSWIRE) -- Progenity, Inc. (NASDAQ: PROG) today announced the pricing of its offering of $75.0 million aggregate principal amount of 7.25% convertible senior notes du
Progenity Announces Pricing of Public Offering of Common Stock
11:50pm, Wednesday, 02'nd Dec 2020
SAN DIEGO, Dec. 02, 2020 (GLOBE NEWSWIRE) -- Progenity, Inc. (“Progenity”) (NASDAQ: PROG), a biotechnology company with an established track record of success in developing and commercializing mo
Progenity Announces Proposed Convertible Senior Notes Offering
09:39pm, Monday, 30'th Nov 2020
SAN DIEGO, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Progenity, Inc. (NASDAQ: PROG) today announced its intention to offer, subject to market and other conditions, $75 million aggregate principal amount of co
Progenity Announces Proposed Public Offering of Common Stock
09:38pm, Monday, 30'th Nov 2020
SAN DIEGO, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Progenity, Inc. (“Progenity”) (NASDAQ: PROG), a biotechnology company with an established track record of success in developing and commercializing mol
High sensitivity and high negative predictive value (NPV) observed for ruling out the risk of preeclampsia High sensitivity and high negative predictive value (NPV) observed for ruling out the risk of
Progenity to Present at 2020 San Antonio Breast Cancer Virtual Symposium
07:30am, Tuesday, 17'th Nov 2020
SAN DIEGO, Nov. 17, 2020 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing pro
Progenity to Participate in the 32nd Annual Piper Sandler Healthcare Conference
07:30am, Monday, 16'th Nov 2020
SAN DIEGO, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing pro
Progenity to Host Preeclampsia Virtual R&D Day on November 20, 2020
07:30am, Friday, 13'th Nov 2020
SAN DIEGO, Nov. 13, 2020 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing pro
Progenity, Inc. (PROG) CEO Harry Stylli on Q3 2020 Results - Earnings Call Transcript
10:30pm, Monday, 09'th Nov 2020
Progenity, Inc. (PROG) CEO Harry Stylli on Q3 2020 Results - Earnings Call Transcript
SAN DIEGO, Nov. 06, 2020 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing pro
Progenity to Report Third Quarter 2020 Financial Results and Provide Corporate Update
08:43am, Tuesday, 03'rd Nov 2020
SAN DIEGO, Nov. 03, 2020 (GLOBE NEWSWIRE) -- Progenity, Inc. (NASDAQ: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing pro
Progenity Announces Successful Achievement of its Preeclampsia Test Analytical Verification Milestone
07:30am, Thursday, 29'th Oct 2020
Announces Expansion of its COVID-19 Testing Offering
Los Angeles, California--(Newsfile Corp. - October 27, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Progenity, Inc
New York, New York--(Newsfile Corp. - October 27, 2020) - Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Progenity, Inc. (NASDAQ: PROG) pursuant and/or trac
Oral and poster presentations feature data on the use of PIL Dx to assess and diagnose SIBO Oral and poster presentations feature data on the use of PIL Dx to assess and diagnose SIBO
